当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

Abstract：

:The prognostic value of proliferative activity and its relationship with steroid hormone receptors and histopathological grade have been demonstrated for breast cancers. However, nothing is known about the underlying mechanisms. In order to understand the chronology of the appearance of increased proliferative activities, we used a series of 760 consecutive breast cancers for which we had obtained S-phase fractions (SPFs) by DNA flow cytometry. When the absolute difference from a DNA index of 1.00 was compared to SPFs, a significant positive correlation was obtained (r = 0.39, p < 0.0001), indicating that the probability of observing a high SPF increases when tumors progressively deviate from diploidy. A highly significant correlation was observed for the hyperploid group when hypertetraploid tumors were excluded, as the SPFs increased progressively as the DNA indices decreased from 2.00 to 1.30. This observation suggested a relationship with the evolution of chromosomal abnormalities as determined by cytogenetic analysis. Indeed, in a subset of 52 cases for which sufficient metaphases were available, there was a highly significant correlation between the SPF values and the proportion of rearranged chromosomes in the tumor cells (r = 0.60, p < 0.0001). When SPFs were separated into low or high using the median value (4.5%), a correlation also existed with the genetic evolution, since they increased from diploidy to hypodiploidy and then, after endoreduplication, from tetraploidy towards triploidy, as determined by the chromosome counts. Our results substantiate the relationship between proliferative activity and steroid hormone receptors which follow the same model.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Remvikos Y,Gerbault-Seureau M,Magdelénat H,Prieur M,Dutrillaux B

doi

10.1007/BF01831474

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

43-9

issue

1-2

eissn

0167-6806

issn

1573-7217

journal_volume

23

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

    abstract：:IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000032922.87541.31

    authors： Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

    更新日期：2004-07-01 00:00:00

  • The effect of thrombospondin-1 on breast cancer metastasis.

    abstract：:Thrombospondin-1 (TSP-1) has been proposed to have both pro-metastatic and anti-metastatic properties. To elucidate its role in breast cancer metastasis, we compared tumor progression in the polyomavirus middle T antigen (Pyt) transgenic mouse and the TSP-1-null Pyt transgenic mouse. We characterized the tumors in the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9992-6

    authors： Yee KO,Connolly CM,Duquette M,Kazerounian S,Washington R,Lawler J

    更新日期：2009-03-01 00:00:00

  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract：:Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3021-8

    authors： Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期：2014-07-01 00:00:00

  • Racial differences in the familial aggregation of breast cancer and other female cancers.

    abstract：:Although breast cancer familial aggregation has been studied in Caucasians, information for African-Americans is scant. We used family cancer history from the Women's Contraceptive and Reproductive Experiences study to assess the aggregation of breast and gynecological cancers in African-American and Caucasian familie...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-2046-9

    authors： Simon MS,Korczak JF,Yee CL,Daling JR,Malone KE,Bernstein L,Marchbanks PA,Folger SG,McDonald JA,Norman SA,Strom BL,Deapen D,Ursin G,Burkman RT,Press MF,Schwartz AG,Spirtas R

    更新日期：2005-02-01 00:00:00

  • A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

    abstract：:Heat shock protein 90 (Hsp90) facilitates maturation and stability of HER2. Combining an Hsp90 inhibitor and trastuzumab has demonstrated anti-tumor effects in patients with HER2+ breast cancer. Adults with measurable, locally advanced or metastatic HER2+ breast cancer and prior trastuzumab treatment were enrolled in ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-013-2510-5

    authors： Modi S,Saura C,Henderson C,Lin NU,Mahtani R,Goddard J,Rodenas E,Hudis C,O'Shaughnessy J,Baselga J

    更新日期：2013-05-01 00:00:00

  • High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

    abstract：:Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine Patients received lapatinib 1,250 mg once daily and capecitabine 2,000 ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1200-9

    authors： Rhee J,Han SW,Cha Y,Ham HS,Kim HP,Oh DY,Im SA,Park JW,Ro J,Lee KS,Park IH,Im YH,Bang YJ,Kim TY

    更新日期：2011-01-01 00:00:00

  • Clinical/genetic features in hereditary breast cancer.

    abstract：:Patients from hereditary breast cancer-prone (HBC) families provide one of the most powerful and potentially cost effective models for cancer prevention and control. Paradoxically, this opportunity is often missed in the clinical practice setting due, in part, to inattention to the family history and/or lack of knowle...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810778

    authors： Lynch HT,Watson P,Conway TA,Lynch JF

    更新日期：1990-02-01 00:00:00

  • The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

    abstract：:The Neoadjuvant response index (NRI) has been proposed as a simple measure of downstaging by neoadjuvant treatment in breast cancer. It was previously found to predict recurrence-free survival (RFS) in triple-negative (TN) breast cancer. It was at least as accurate as the standard binary system, the absence or presenc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3510-4

    authors： Jebbink M,van Werkhoven E,Mandjes IA,Wesseling J,Lips EH,Vrancken Peeters MJ,Loo CE,Sonke GS,Linn SC,Falo Zamora C,Rodenhuis S

    更新日期：2015-08-01 00:00:00

  • Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome.

    abstract：:Whether or not breast cancer can be a feature of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome has been debated. In order to clarify if defective mismatch repair (MMR) may indeed play a role in breast cancer, we used the Danish HNPCC register to identify all breast cancers that occurred in MMR gene mu...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0449-3

    authors： Jensen UB,Sunde L,Timshel S,Halvarsson B,Nissen A,Bernstein I,Nilbert M

    更新日期：2010-04-01 00:00:00

  • Current status of paclitaxel in the treatment of breast cancer.

    abstract：:Paclitaxel is a highly active single agent as therapy for previously untreated as well as doxorubicin-refractory metastatic breast cancer, with associated response rates of 62% and 20-48%, respectively. Complete responses with paclitaxel occur chiefly in breast cancer patients whose metastatic disease has not been pre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666068

    authors： O'Shaughnessy JA,Cowan KH

    更新日期：1995-01-01 00:00:00

  • The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.

    abstract：BACKGROUND:The aromatase inhibitors (AIs) are increasingly surpassing tamoxifen as the endocrine treatment of choice for postmenopausal breast cancer patients. With their increasing use, there is concern that they are being inadvertently prescribed to pre- and peri-menopausal women. METHODS:As part of a continuing med...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9031-9

    authors： Gainford MC,McCready D,Clemons M

    更新日期：2006-04-01 00:00:00

  • Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.

    abstract：:Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. However, the immunocompetence of TIL and the possibility to consistentl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/A:1024938215782

    authors： Kass R,Bellone S,Palmieri M,Canè S,Bignotti E,Henry-Tillman R,Hutchins L,Cannon MJ,Klimberg S,Santin AD

    更新日期：2003-08-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract：:Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-4321-9

    authors： Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期：2005-09-01 00:00:00

  • Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.

    abstract：:Estrogen receptor beta (ERbeta) is widely expressed in mammary epithelium. ERbeta expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERbeta expression in mammary epithelial cells. We knocked down ERbeta transcript levels in ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0413-2

    authors： Treeck O,Lattrich C,Springwald A,Ortmann O

    更新日期：2010-04-01 00:00:00

  • Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.

    abstract：PURPOSE:Breast terminal duct lobular units undergo two distinctive physiological processes of involution: age-related lobular involution (LI), which is gradual and associated with decreased breast cancer risk, and postlactational involution, which is relatively precipitous, occurs with weaning, and has been associated ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4413-3

    authors： Stallings-Mann ML,Heinzen EP,Vierkant RA,Winham SJ,Hoskin TL,Denison LA,Nassar A,Hartmann LC,Visscher DW,Frost MH,Sherman ME,Degnim AC,Radisky DC

    更新日期：2017-11-01 00:00:00

  • Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland.

    abstract：BACKGROUND:The genes mutated in the cancer-prone syndrome, xeroderma pigmentosum (XP genes), have been well studied both biochemically and mechanistically. These genes are important components of the DNA nucleotide excision repair (NER) pathway, which protects against environmentally-induced cancers. XP genes are also ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9263-3

    authors： Jorgensen TJ,Visvanathan K,Ruczinski I,Thuita L,Hoffman S,Helzlsouer KJ

    更新日期：2007-01-01 00:00:00

  • Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials.

    abstract：PURPOSE:To examine the outcomes of endocrine naive patients treated with tamoxifen as initial endocrine therapy for metastatic breast cancer. Data were obtained from the long-term follow-up of two previously published randomized trials. PATIENTS AND METHODS:All patients received tamoxifen 20 mg po in a single daily do...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005758127114

    authors： Kuss JT,Muss HB,Hoen H,Case LD

    更新日期：1997-02-01 00:00:00

  • Larger axillary metastases in obese women and smokers with breast cancer--an influence by host factors on early tumor behavior.

    abstract：:To better define the influence by host factors on very early breast cancer behavior, we retrospectively analyzed nodal status, diameter of the largest axillary metastasis (M), diameter of the primary tumor (P), the M/P ratio, tumor estrogen receptor status, age, obesity, and smoking habits in 176 women with node-posit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00689833

    authors： Daniell HW,Tam E,Filice A

    更新日期：1993-01-01 00:00:00

  • Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.

    abstract：:Tamoxifen has been used for the treatment of breast cancer since the 1970s, but is considered a carcinogen because it has been linked to liver cancer in rats and an increased risk of endometrial cancer in patients. In rats, DNA adducts appear to be responsible for carcinogenesis, but their contribution to carcinogenes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006311214152

    authors： Hellmann-Blumberg U,Taras TL,Wurz GT,DeGregorio MW

    更新日期：2000-03-01 00:00:00

  • Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

    abstract：:Acquired resistance to endocrine therapy in breast cancer is a major clinical problem. Previous reports have demonstrated that cell models of acquired endocrine resistance have altered cell-matrix adhesion and a highly migratory phenotype, features which may impact on tumour spread in vivo. Focal adhesion kinase (FAK)...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0857-4

    authors： Hiscox S,Barnfather P,Hayes E,Bramble P,Christensen J,Nicholson RI,Barrett-Lee P

    更新日期：2011-02-01 00:00:00

  • Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

    abstract：:Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this study was to disclose the prognostic significance of different morphological categories of ICC-positive cells according to treatment status an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2439-8

    authors： Synnestvedt M,Borgen E,Schlichting E,Schirmer CB,Renolen A,Giercksky KE,Nesland JM,Naume B

    更新日期：2013-04-01 00:00:00

  • Utilization of hypofractionated whole-breast radiation therapy in patients receiving chemotherapy: a National Cancer Database analysis.

    abstract：PURPOSE:Results from four major hypofractionated whole-breast radiotherapy (HF-WBRT) trials have demonstrated equivalence in select patients with early-stage breast cancer when compared with conventionally fractionated WBRT (CF-WBRT). Because relatively little data were available on patients receiving neoadjuvant or ad...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4345-y

    authors： Diwanji TP,Molitoris JK,Chhabra AM,Snider JW,Bentzen SM,Tkaczuk KH,Rosenblatt PY,Kesmodel SB,Bellavance EC,Cohen RJ,Cheston SB,Nichols EM,Feigenberg SJ

    更新日期：2017-09-01 00:00:00

  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract：PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05488-2

    authors： Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期：2020-02-01 00:00:00

  • Patients' understanding of their own disease and survival potential in patients with metastatic breast cancer.

    abstract：PURPOSE:To investigate the effect of understanding their own disease by patients with metastatic breast cancer on their survival potential after being informed by their physician. PATIENTS AND METHODS:Two hundred and fourteen women with metastatic breast cancer who participated in a multi-institutional, randomized pha...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1023/a:1006483214678

    authors： Okamura H,Yamamoto N,Watanabe T,Katsumata N,Takashima S,Adachi I,Kugaya A,Akechi T,Uchitomi Y

    更新日期：2000-05-01 00:00:00

  • A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.

    abstract：PURPOSE:Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2-ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. R...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-020-05626-1

    authors： Watanabe J,Saito M,Horimoto Y,Nakamoto S

    更新日期：2020-05-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • Women with breast cancer report substantially more disease- and treatment-related side or late effects than registered by clinical oncologists: a cross-sectional study of a standard follow-up program in an oncological department.

    abstract：BACKGROUND:Follow-up after breast cancer treatment is standard due to the risk of development of new primary cancers and recurrent disease. The aim of the present study was to evaluate a standard follow-up program in an oncological department by assessing: (1) Symptoms or signs of new primary cancer or recurrent diseas...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4301-x

    authors： Ellegaard MB,Grau C,Zachariae R,Jensen AB

    更新日期：2017-08-01 00:00:00

  • EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

    abstract：:EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1380-y

    authors： Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

    更新日期：2011-06-01 00:00:00

  • Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.

    abstract：:To reduce the risk of adjustment problems for breast cancer patients in mainland China, we examined the efficacy of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), delivered after breast surgery to (a) increase protective factors of social support, hope for the future, etc.; (b) decrease ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-016-3881-1

    authors： Ye ZJ,Liang MZ,Qiu HZ,Liu ML,Hu GY,Zhu YF,Zeng Z,Zhao JJ,Quan XM

    更新日期：2016-08-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract：:In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00713399

    authors： Jordan VC

    更新日期：1995-01-01 00:00:00